Savara (NASDAQ:SVRA) Shares Up 7.3% – Still a Buy?

Savara Inc. (NASDAQ:SVRA)’s stock price shot up 7.3% during trading on Wednesday . The stock traded as high as $4.44 and last traded at $4.4730. 992,334 shares were traded during trading, a decline of 25% from the average session volume of 1,324,706 shares. The stock had previously closed at $4.17.

Wall Street Analysts Forecast Growth

SVRA has been the subject of a number of recent research reports. Wells Fargo & Company assumed coverage on shares of Savara in a research note on Monday, October 20th. They set an “overweight” rating and a $7.00 price target for the company. Citigroup restated an “outperform” rating on shares of Savara in a research report on Thursday, October 23rd. Lifesci Capital raised Savara to a “strong-buy” rating in a research note on Tuesday, October 14th. Citizens Jmp cut their target price on Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 13th. Finally, HC Wainwright raised their target price on Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $8.29.

Savara Stock Performance

The firm has a market cap of $951.21 million, a P/E ratio of -9.27 and a beta of 0.45. The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The stock’s 50-day moving average is $3.82 and its 200 day moving average is $3.07.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, research analysts predict that Savara Inc. will post -0.45 earnings per share for the current year.

Institutional Trading of Savara

Several hedge funds have recently bought and sold shares of the stock. Sivia Capital Partners LLC lifted its position in Savara by 9.1% during the 2nd quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock worth $95,000 after buying an additional 3,459 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after acquiring an additional 4,626 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Savara by 17.6% during the second quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock valued at $87,000 after purchasing an additional 5,687 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Savara by 14.2% during the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the last quarter. Finally, Sio Capital Management LLC grew its stake in Savara by 1.0% in the second quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock valued at $1,657,000 after purchasing an additional 7,197 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.